Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out whether either trastuzumab or the combination of
trastuzumab and pertuzumab with standard chemotherapy shows more activity against
gastro-oesophageal adenocarcinoma than standard chemotherapy given before and after surgery
and it can be safely administered.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC